A NEW GENERATION OF DIAGNOSTIC SOLUTIONS
THE PROBLEM
Breast cancer is the most frequent cancer in women worldwide: about 1 out of 8 women will develop breast cancer over their lifetime. Approximately 25% of them will
suffer relapse and develop metastases. To decrease breast cancer mortality there is an urgent need to improve early breast cancer detection and monitoring after therapy.
OUR SOLUTION
We have developed a blood test for breast cancer screening and early detection of relapses. The test is based on the analysis of multiple, specific biomarkers derived from blood leukocytes. It can be integrated into current diagnostic procedures and will assist doctors in making decisions for personalized treatments.
VALUES AND BENEFITS
SIMPLE AND AFFORDABLE
Fully integrated into clinical practice
MINIMALLY INVASIVE
Routine blood test analysis
PRECISE
>98% specificity and 77-93% sensitivity
IMPROVED SURVIVAL
Early detection
PERSONALIZED TREATMENTS
Rapid adaptation of therapy